OBJECTIVE: To examine trends in glucocorticoid (GC) use and dosing among patients diagnosed with rheumatoid arthritis (RA) over time. METHODS: A population-based inception cohort of RA patients diagnosed during 1980-2007 was followed longitudinally through their medical records until death, migration, or December 31, 2008. GC start and stop dates were collected, along with doses in prednisone equivalents. RESULTS: The study population comprised 349 patients (68% women) diagnosed in 1980-1994 and 464 (69% women) diagnosed in 1995-2007, with a median followup of 15.3 and 5.7 years, respectively. A higher proportion of patients started GCs in their first year of disease in 1995-2007 (68% versus 36%; P < 0.001), but the starting dose (mean 8.7 versus 10.3 mg; P = 0.08) and cumulative dose in the first year of use (mean 1.8g [mean daily dose 4.9 mg] versus 2.1 gm [mean daily dose 5.8 mg]; P = 0.48) were not different. A higher proportion also discontinued GCs in their first year of disease in the 1995-2007 cohort (P < 0.001). These differences in GC initiation and discontinuation persisted throughout followup. Prevalence of GC use was higher in the 1995-2007 cohort for the first 3 years of disease. CONCLUSION: More patients are starting GCs early in their disease course now compared to previously, which is consistent with established treatment guidelines. A higher proportion are also discontinuing GCs, but the proportion of patients taking GCs at any given point of disease during the first 4 years is higher now than previously. Despite early addition of a disease-modifying antirheumatic drug, some patients may not be able to discontinue GCs over the long term.
OBJECTIVE: To examine trends in glucocorticoid (GC) use and dosing among patients diagnosed with rheumatoid arthritis (RA) over time. METHODS: A population-based inception cohort of RApatients diagnosed during 1980-2007 was followed longitudinally through their medical records until death, migration, or December 31, 2008. GC start and stop dates were collected, along with doses in prednisone equivalents. RESULTS: The study population comprised 349 patients (68% women) diagnosed in 1980-1994 and 464 (69% women) diagnosed in 1995-2007, with a median followup of 15.3 and 5.7 years, respectively. A higher proportion of patients started GCs in their first year of disease in 1995-2007 (68% versus 36%; P < 0.001), but the starting dose (mean 8.7 versus 10.3 mg; P = 0.08) and cumulative dose in the first year of use (mean 1.8g [mean daily dose 4.9 mg] versus 2.1 gm [mean daily dose 5.8 mg]; P = 0.48) were not different. A higher proportion also discontinued GCs in their first year of disease in the 1995-2007 cohort (P < 0.001). These differences in GC initiation and discontinuation persisted throughout followup. Prevalence of GC use was higher in the 1995-2007 cohort for the first 3 years of disease. CONCLUSION: More patients are starting GCs early in their disease course now compared to previously, which is consistent with established treatment guidelines. A higher proportion are also discontinuing GCs, but the proportion of patients taking GCs at any given point of disease during the first 4 years is higher now than previously. Despite early addition of a disease-modifying antirheumatic drug, some patients may not be able to discontinue GCs over the long term.
Authors: J N Hoes; J W G Jacobs; M Boers; D Boumpas; F Buttgereit; N Caeyers; E H Choy; M Cutolo; J A P Da Silva; G Esselens; L Guillevin; I Hafstrom; J R Kirwan; J Rovensky; A Russell; K G Saag; B Svensson; R Westhovens; H Zeidler; J W J Bijlsma Journal: Ann Rheum Dis Date: 2007-07-27 Impact factor: 19.103
Authors: Marije F Bakker; Johannes W G Jacobs; Paco M J Welsing; Suzanne M M Verstappen; Janneke Tekstra; Evelien Ton; Monique A W Geurts; Jacobine H van der Werf; Grietje A van Albada-Kuipers; Zalima N Jahangier-de Veen; Maaike J van der Veen; Catharina M Verhoef; Floris P J G Lafeber; Johannes W J Bijlsma Journal: Ann Intern Med Date: 2012-03-06 Impact factor: 25.391
Authors: Johannes W J Bijlsma; Jos N Hoes; Amalia A Van Everdingen; Suzan M M Verstappen; Johannes W G Jacobs Journal: Ann N Y Acad Sci Date: 2006-06 Impact factor: 5.691
Authors: Amalia A van Everdingen; Johannes W G Jacobs; Dirk R Siewertsz Van Reesema; Johannes W J Bijlsma Journal: Ann Intern Med Date: 2002-01-01 Impact factor: 25.391
Authors: K G Saag; R Koehnke; J R Caldwell; R Brasington; L F Burmeister; B Zimmerman; J A Kohler; D E Furst Journal: Am J Med Date: 1994-02 Impact factor: 4.965
Authors: Elena Myasoedova; Sherine E Gabriel; Eric L Matteson; John M Davis; Terry M Therneau; Cynthia S Crowson Journal: J Rheumatol Date: 2017-04-01 Impact factor: 4.666
Authors: Michael D George; Joshua F Baker; Beth Wallace; Lang Chen; Qufei Wu; Fenglong Xie; Huifeng Yun; Jeffrey R Curtis Journal: Arthritis Care Res (Hoboken) Date: 2021-10-07 Impact factor: 4.794
Authors: Michael D George; Joshua F Baker; Kevin Winthrop; Jesse Y Hsu; Qufei Wu; Lang Chen; Fenglong Xie; Huifeng Yun; Jeffrey R Curtis Journal: Ann Intern Med Date: 2020-09-22 Impact factor: 25.391
Authors: Jorge A Zamora-Legoff; Sara J Achenbach; Cynthia S Crowson; Megan L Krause; John M Davis; Eric L Matteson Journal: Clin Rheumatol Date: 2016-03-29 Impact factor: 2.980
Authors: Michael D George; Jesse Y Hsu; Sean Hennessy; Lang Chen; Fenglong Xie; Jeffrey R Curtis; Joshua F Baker Journal: Epidemiology Date: 2022-01-01 Impact factor: 4.822
Authors: David M Kern; Lawrence Chang; Kalyani Sonawane; Cynthia J Larmore; Natalie N Boytsov; Ralph A Quimbo; Joseph Singer; John T Hinton; Sze-Jung Wu; Andre B Araujo Journal: Rheumatol Ther Date: 2018-05-30